The current study aimed to develop the novel lipid base formulations to a target and restrict the cellular expansion of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this objective, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated aided by the anti-Her-2 fab’ and encapsulated FASN siRNA…[Read more]